Post-market Review of Pulmonary Arterial Hypertension (PAH) Medicines

from Australian Health Economics Society at http://bit.ly/2s5csFv on June 25, 2017 at 10:41AM


The Department of Health is commencing consultation on the Post-market Review of Pulmonary Arterial Hypertension (PAH) Medicines, which are listed on the Pharmaceutical Benefits Scheme (PBS). The purpose of the Review is to consider the cost-effectiveness of PAH medicines, in the context of the latest available evidence and Quality Use of Medicines. The Review was […]

Advertisements